RecruitingNot ApplicableNCT05874674
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study
Sponsor
Wonju Severance Christian Hospital
Enrollment
100 participants
Start Date
Dec 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Comparison nafamostat and low molecular weight heparin among dialysis patients
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria1
- platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month
Exclusion Criteria1
- cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNafamostat Mesylate
Comparison effect of nafamostat and cnoxan
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05874674
Related Trials
LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)
NCT064467399 locations
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
NCT063378383 locations
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
NCT075238803 locations
The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies
NCT062294831 location
Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
NCT070327921 location